Study guide
8.2 Multimorbidity and Prioritization
ANCC Family Nurse Practitioner FNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Test Day 1.3 Blueprint Weights, TCO Dates, and Study Strategy
2 Assessment Foundations
2.1 Population Health Promotion and Screening 2.2 Comprehensive History and Physical 2.3 Focused History and Physical 2.4 Age-Specific Screening Schedules
3 Function, Risk, and Lifespan Assessment
3.1 Functional Assessment 3.2 Risk Assessment and Social Determinants 3.3 Pediatric Developmental Assessment 3.4 Adolescent, Adult, and Geriatric Assessment
4 Diagnosis Foundations
4.1 Pathogenesis and Pathophysiology 4.2 Diagnostic Test and Procedure Selection 4.3 Interpreting Labs and Imaging 4.4 Normal vs Abnormal Physiologic Change
5 Differential Diagnosis
5.1 Formulating Differential Diagnoses 5.2 Red Flags and Emergency Identification 5.3 Diagnostic Reasoning Traps
6 Prevention and Anticipatory Guidance
6.1 Primary, Secondary, and Tertiary Prevention 6.2 Pediatric and Adolescent Anticipatory Guidance 6.3 Adult and Geriatric Anticipatory Guidance 6.4 Immunization Planning Across the Lifespan
7 Guidelines, Culture, and Evidence
7.1 Crisis, Safety, and End-of-Life Planning 7.2 Clinical Guidelines and Standards of Care 7.3 Culturally and Ethnically Sensitive Practice 7.4 Evidence-Based Research Appraisal
8 Care Plans and Shared Decisions
8.1 Shared Decision-Making 8.2 Multimorbidity and Prioritization 8.3 Referral, Comanagement, and Transitions
9 Pharmacotherapeutics
9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics 9.2 Interactions, Contraindications, and Monitoring 9.3 Special-Population Prescribing 9.4 High-Alert Medications and Analgesic Safety
10 Cardiovascular Primary Care
10.1 Cardiovascular Diagnosis 10.2 Cardiovascular Pharmacotherapy 10.3 Nonpharmacologic Cardiovascular Management 10.4 Lifespan Cardiovascular Issues
11 Respiratory Primary Care
11.1 Respiratory Diagnosis 11.2 Respiratory Pharmacotherapy 11.3 Lifespan Respiratory Care
12 Endocrine and Metabolic Primary Care
12.1 Diabetes Diagnosis and Monitoring 12.2 Diabetes Pharmacotherapy 12.3 Thyroid and Other Endocrine Disorders 12.4 Obesity and Metabolic Disease
13 Gastrointestinal Primary Care
13.1 Gastrointestinal Diagnosis 13.2 GI Pharmacotherapy and Nutrition 13.3 Lifespan Gastrointestinal Care
14 GU, Renal, and Reproductive Primary Care
14.1 GU and Renal Diagnosis and Management 14.2 Women's Reproductive Health 14.3 Pregnancy and Postpartum Primary Care 14.4 Men's Health and Sexual Function
15 HEENT, Skin, and Musculoskeletal
15.1 HEENT Diagnosis and Management 15.2 Integumentary Diagnosis and Management 15.3 Musculoskeletal Diagnosis 15.4 MSK Procedures and Nonpharmacologic Care
16 Neuro, Psych, Heme, Immune, and Infection
16.1 Neurological Diagnosis and Management 16.2 Psychiatric Diagnosis and Substance Use 16.3 Hematopoietic and Immune Disorders 16.4 Common Infections and Anti-Infectives
17 Clinical Delivery Skills
17.1 Office Procedures and Nonpharmacologic Treatment 17.2 Patient-Specific Education 17.3 Therapeutic Communication 17.4 Comprehensive Documentation
18 Professional Practice
18.1 Legal and Ethical Implications 18.2 Health IT, EHR, and AI Ethics 18.3 Regulatory Guidelines: Reportable Disease and Abuse 18.4 APRN Scope, Standards, and FNP Role
19 Outcome Evaluation
19.1 Ethical and Legal Evaluation Issues 19.2 Pharmacotherapeutic Outcome Monitoring 19.3 Nonpharmacologic Outcome Monitoring 19.4 Clinical Data, PROs, and Treatment Efficacy
20 Follow-Up, Systems, and Exam Strategy
20.1 Follow-Up Intervals and Surveillance 20.2 Treatment Adjustment and Deprescribing 20.3 Resource Management and Care Coordination 20.4 Exam-Day Strategy and TCO Review
8.2 Multimorbidity and Prioritization
Key Takeaways Explain This Topic AI
ANCC multimorbidity looks like a 78-year-old with HFrEF, CKD, type 2 diabetes, depression, and osteoarthritis — you cannot fire ADA, ACC/AHA, KDIGO, and the pain guideline in one 20-minute visit.
Rank in this order: what will kill or disable first; what the patient says matters most; which drugs already fight each other.
Classic collisions: systemic NSAID in HF or CKD (ACE + diuretic + NSAID triple whammy), stacked hypotensives, and sliding-scale insulin as the sole insulin plan in an older adult.
Deprescribing is a plan — indication, taper when needed, monitor, follow-up — not a failure to “optimize.” Aspirin for primary prevention at this age and sliding-scale-only insulin are first-line chopping-block items.
Replace the one-problem-per-visit myth with time-boxed agenda setting: the patient’s top one or two goals plus the FNP’s safety item, and a written sequence for the rest.
Last updated: August 2026
ANCC does not give you a 22-year-old with one problem and a clean guideline. Domain III Planning is built for the person who already has too many guidelines . A typical scored vignette looks like this: 78 years old, heart failure with reduced ejection fraction, CKD, type 2 diabetes, depression, osteoarthritis , eleven medications, a daughter who wants “all the numbers at target,” and a 20-minute slot. If you try to satisfy ADA, ACC/AHA, KDIGO, AGS Beers, and the pain guideline in one visit, you will write an elegant plan the patient cannot swallow, cannot afford, and that may land them in the hospital.
Multimorbidity is not “several problems on the list.” It is interacting diseases, interacting drugs, competing outcomes, and a treatment burden that is itself a disease . Planning means choosing what to optimize now , what to monitor, and what to deliberately leave imperfect. Single-disease guidelines (Section 7.2) are still required knowledge. They are not a stack you execute from the top.
You cannot fire every guideline at once
Guideline pressure What it wants in this 78-year-old Why it collides
ADA / diabetes A1c often <7% in healthier adults; multiple agents; tight fasting numbers Hypoglycemia, falls, complexity. In complex older adults, ADA and geriatric consensus commonly accept about 8–8.5% (individualize).
ACC/AHA HF Foundational GDMT: ARNI (or ACE/ARB), evidence-based beta blocker, MRA, SGLT2 inhibitor; some patients also a loop diuretic SBP 100, eGFR 28, potassium 5.1. Four pressure-lowering, kidney-facing drugs at once can disable the person you are trying to save.
KDIGO CKD Avoid nephrotoxins; dose by eGFR; ACE inhibitor or ARB for albuminuria; often SGLT2 Same ACE/ARNI and SGLT2 cardiology wants; NSAID the patient wants for knees; metformin already dose-limited.
Pain / OA Systemic NSAID, sometimes with a PPI; stay active NSAID in HF and CKD is a classic exam trap: fluid retention, AKI, blunted diuretic and ACE effect — the triple whammy of ACE + diuretic + NSAID.
Depression Start or titrate an antidepressant; consider augmentation Hyponatremia on SSRIs in older adults, falls, QT with some agents, drug–drug interactions with HF meds. Untreated depression still kills adherence and function.
Primary-prevention extras Aspirin, sliding-scale coverage for “high readings,” a fifth antihypertensive to hit 120 mm Hg USPSTF Grade D for initiating aspirin at 60 and older ; Beers: avoid sliding-scale insulin as the sole regimen; hypotension is a fall.
The FNP priority is not “the newest society statement.” It is a rank .
Three ranking questions (use them in this order)
1. What will kill or disable first? Near-term mortality and irreversible disability outrank cosmetic numbers. In the 78-year-old, decompensated HF, hyperkalemia, hypoglycemia, AKI, and a hip fracture from a fall beat a 0.4-point A1c improvement and beat a screening colonoscopy you should have stopped considering given frailty and a short benefit horizon. Write the kill/disable list before you write the prescription list.
2. What does the patient say matters most? After safety, function and stated goals win. “I want to walk to the mailbox and stay in this house” is a better north star than “A1c 6.8%.” Ask it out loud. If the daughter wants every number at target and the patient wants fewer pills and less dizziness, the patient (if they have capacity) owns the values. Document the goal in the plan so the next clinician does not undo it.
3. Which drugs are already fighting each other? Before you add, look for:
NSAID in CKD or HF , and the ACE + loop + NSAID triple whammy.
Stacked hypotensives — ARNI + loop + SGLT2 + MRA + a leftover thiazide, sitting SBP 96, “lightheaded when I stand.”
Sliding-scale insulin complexity in an older adult who cannot see the syringe, lives alone, and has variable intake. Beers: do not use sliding scale as the sole insulin plan.
Duplicate serotonergic or anticholinergic loads (diphenhydramine PM + oxybutynin + amitriptyline for “nerve pain”).
Glyburide or other long-acting sulfonylureas that convert diabetes into a fall-and-hypoglycemia disease.
If a new prescription does not survive those three questions, it does not go on today’s plan, even if a single-disease app flashes red.
The 78-year-old, worked
R. is 78. HFrEF EF 35%, eGFR 32 and falling slowly, A1c 8.1% on metformin 500 mg daily and sliding-scale lispro “when the number is high,” PHQ-9 of 14, bilateral knee OA, 14 medications including ibuprofen 600 mg three times daily, lisinopril 40 mg, furosemide 40 mg, metoprolol succinate 50 mg, sertraline 50 mg, and aspirin 81 mg (no prior ASCVD). BP 108/64 sitting, 90/58 standing. She has gained 4 lb in 5 days. She says, “I want to stop feeling awful and I do not want another specialist visit this month.”
Today’s kill/disable list: volume overload / HF exacerbation , orthostatic hypotension and fall , NSAID-related AKI and HF worsening , hypoglycemia from sliding scale , depression that is already impairing function . A1c 8.1% is not the emergency. The aspirin is primary prevention in a 78-year-old — a deprescribing candidate, not a quality-measure win.
A coherent plan for this visit, not for the entire year:
Treat the HF now: daily weights, red flags of about 2–3 lb overnight or 5 lb in a week , adjust the loop, review salt and NSAID, and decide whether she is wet enough for same-week cardiology or the ED.
Stop the ibuprofen. Offer acetaminophen first-line, a topical NSAID only if you judge systemic exposure acceptable, physical therapy, and a later discussion of intra-articular injection. Do not “just add a PPI and keep the ibuprofen.”
Stop sliding-scale-only lispro. Either a simple basal plan if insulin is truly needed, or no insulin if A1c 8.1% is acceptable for this person; teach hypoglycemia.
Deprescribe aspirin unless a hidden ASCVD history appears.
Do not add a second oral hypoglycemic today just because ADA’s healthier-adult target is <7%. Consider an SGLT2 later — it helps HF and CKD — but not on the afternoon she is hypotensive and wet.
Name depression as a priority for the next visit if today is full, or start/adjust if she identifies mood as the thing that matters most and you have five clean minutes. Do not start a second serotonergic agent on autopilot.
Time-box: HF safety + NSAID stop + insulin simplification + one patient-identified goal. Everything else goes on a written sequence.
That plan will look “incomplete” to a student who grades themselves against five guidelines. On ANCC, incomplete-and-safe beats complete-and-harmful .
Deprescribing is a plan, not a failure
Deprescribing has an indication, a taper when needed, a monitor, and a follow-up, just like starting a drug. Put it in the plan in those four parts. Chapter 20.2 will go deeper on outcome-driven deprescribing; Planning is where you decide that stopping is today’s intervention.
Candidate Why it is on the chopping block How you stop it
Aspirin for primary prevention at ≥60 USPSTF Grade D to initiate at 60+; bleed risk rises with age, CKD, and NSAID Stop; explain the Grade D logic in one sentence
Sliding-scale insulin as the only insulin Beers; hypoglycemia; complexity Replace with a simple plan or with no insulin if the A1c target allows
NSAID in HF or CKD Fluid, AKI, blunted GDMT Stop; substitute a non-NSAID analgesia plan
PPI without an indication Infection, malabsorption, extra pill Taper if long-term; do not yank after a recent bleed
Benzodiazepine or sedating antihistamine Falls, delirium Slow taper; never cold-turkey a long-term benzo in a 20-minute visit
Glyburide / “coverage” culture Prolonged hypoglycemia Stop; use metformin if eGFR allows, an SGLT2 for HF/CKD later, or simpler insulin
Third or fourth antihypertensive when dizzy Falls outweigh a theoretical 4 mm Hg Hold or reduce the least useful agent
Write “we are not intensifying A1c because hypoglycemia risk exceeds microvascular benefit at age 78 with HF” in the note. That sentence is the plan. It prevents the covering NP from adding glipizide next Tuesday.
The one-problem-per-visit myth versus time-boxed agenda setting
“One problem per visit” is a clinic-throughput slogan, not a standard of care, and it is a bad ANCC answer in multimorbidity. The interacting problems are the visit. Refusing to hear the second problem is how NSAID-in-HF gets missed.
The adult skill is agenda setting with a clock :
Ask: “What are the two things that must be better when you leave?”
Add your non-negotiable safety item (the 4 lb gain, the potassium, the suicidal-ideation screen).
Say the time out loud: “We have 20 minutes. We will do the swelling and the ibuprofen today. Your A1c and the depression medication get a visit next week. If something worse starts tonight, here is exactly what to do.”
Give a written sequence so the patient does not experience the deferral as dismissal.
Do not confuse agenda setting with ignoring red flags. If the “second problem” is chest pain or new unilateral weakness, it becomes the only problem and the destination is the ED (Section 8.3).
A related trap is the opposite: the FNP who tries to close every open quality metric because the dashboard is red. Dashboard A1c, BP, and statin checkboxes do not outrank syncope, AKI, or hypoglycemia. Sequence the metrics across visits and document why a metric is intentionally not met.
Competing guidelines → FNP priority rule
Collision Single-disease reflex FNP priority rule
A1c 8.1% in a frail 78-year-old versus ADA <7% Add insulin or a second oral now Individualize; prevent hypoglycemia and falls first
Knee pain versus HF/CKD Start naproxen No systemic NSAID; non-NSAID plan; treat HF
HFrEF GDMT versus SBP 96 and eGFR 28 Start ARNI + MRA + SGLT2 today Sequence GDMT; fix volume; do not stack four hypotensives on day one
Depression versus polypharmacy Add a second antidepressant at the same visit you rewrite the entire cardiac list Treat mood, but one major change at a time unless suicide risk forces the issue
Screening calendar versus limited prognosis Keep ordering mammogram, colonoscopy, and A1c every 3 months Stop low-yield screening; keep high-yield safety labs
Daughter’s targets versus patient’s function Order the full panel and three referrals Patient goals + kill/disable list; referrals only if they change near-term safety
Quality-metric A1c / BP / statin checkboxes versus dizziness Intensify to hit the dashboard Metrics do not outrank syncope, AKI, or hypoglycemia
Exam shorthand: kill/disable first, goals second, interactions third, everything else sequenced. If an option in the stem intensifies three guidelines at once in a dizzy 78-year-old, it is almost never correct. If an option stops the NSAID, simplifies insulin, and books a short-interval HF follow-up, it is usually the plan ANCC wants.